Semaglutide: a game changer for metabolic diseases?
Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) molecule approved for the treatment of both type 2 diabetes (T2D) and obesity. Semaglutide has a greater impact on glycated haemoglobin (HbA1c) reduction, compared to other GLP-1 RAs, and is the first molecule of this class availab...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2022-04-01
|
| Series: | Exploration of Medicine |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/em/Article/100183 |